Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.
about
Optimizing treatment success in multiple sclerosisDisease-modifying treatments for multiple sclerosis - a review of approved medicationsMultiple sclerosis-a quiet revolutionRevised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple SclerosisRelapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.Imaging as an Outcome Measure in Multiple Sclerosis.Outcome Measures in Clinical Trials for Multiple Sclerosis.(-)-β-Caryophyllene, a CB2 Receptor-Selective Phytocannabinoid, Suppresses Motor Paralysis and Neuroinflammation in a Murine Model of Multiple Sclerosis.Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations.Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.Decision making under uncertainty, therapeutic inertia, and physicians' risk preferences in the management of multiple sclerosis (DIScUTIR MS)Effect of interferon-β1α therapy on multiple sclerosis based on gadolinium-enhancing or active T2 magnetic resonance imaging outcomes: a meta-analysis.Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.Defining Disease Activity and Response to Therapy in MS.MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease.Twenty-five years of progress: the view from NIMH and NINDSLong-term evolution of multiple sclerosis disability in the treatment era.Assessing treatment response to interferon-β: is there a role for MRI?Herding: a new phenomenon affecting medical decision-making in multiple sclerosis care? Lessons learned from DIScUTIR MSDecision-making in Multiple Sclerosis: The Role of Aversion to Ambiguity for Therapeutic Inertia among Neurologists (DIScUTIR MS).The emerging agenda of stratified medicine in neurology.The challenges of measuring disability accumulation in relapsing-remitting multiple sclerosis: evidence from interferon beta treatments.Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions.Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis.The future of multiple sclerosis treatments.Inosine, an Endogenous Purine Nucleoside, Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis: a Role for A2A Adenosine Receptor.No evidence of disease activity in multiple sclerosis patients.The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.Treatment decisions in multiple sclerosis - insights from real-world observational studies.Prognostic biomarkers of IFNb therapy in multiple sclerosis patients.Predictors of long-term disability accrual in relapse-onset multiple sclerosis.(1)H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis.The transition from first-line to second-line therapy in multiple sclerosis.Predictive value of early brain atrophy on response in patients treated with interferon βA 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.Overcoming Therapeutic Inertia in Multiple Sclerosis Care: A Pilot Randomized Trial Applying the Traffic Light System in Medical Education.Switching therapies in multiple sclerosis.Defining and scoring response to IFN-β in multiple sclerosis.
P2860
Q26771968-BE5D3327-5F5D-4C52-A8E7-DB47570A4B3DQ26777329-F2F4FAB8-E2F4-4D39-BDB0-55350C8B0DC2Q26826930-64F3CB14-F5D0-4D27-853C-B3BCF9AB0886Q30278095-F674A221-AECB-44D7-8C56-F7D96B41B538Q31117462-24104E6E-52B3-44A1-A55F-0363D1362D52Q31134617-CF7FD21E-8BA2-41FA-BABF-2FDA32329C7BQ31160866-837437FB-D434-4617-BE6F-5A4AE1664557Q33624245-A111316E-050D-4E9E-AA25-7FB9127FF653Q33692568-3DA8C4B7-7016-4076-95F8-C2CC8AA3E137Q33755345-22B78142-B186-4BC7-A18F-D6D2E9066B7BQ36008726-40090729-5B7E-4C84-8DAA-9A1F3A8E5379Q36110871-4831F54C-E343-4B53-87A0-0F3E803620A3Q36352813-5997DD7C-5A06-4346-B450-BB4FEEDD3210Q36357501-C414AE3D-FCB5-4A9A-BDD0-52B3B7F68A7AQ36400004-5BDDECCA-DC56-4330-962B-A620652AF84EQ36667808-FCDC7B54-1D50-4FDF-B775-155B9EDCB03AQ37384323-5007D548-EBD1-4CD2-8339-B7D1BBB517BDQ37409279-1E68F003-D4FC-4232-A796-7A53BEFDE1CFQ37518057-165D8B20-B733-45CE-A6E2-C01EA21C638CQ37626730-382D4D23-A402-43D5-B181-F5FACD65F733Q37672368-34859710-2467-4F77-8723-46033D2D8DC5Q38169977-C7CFA2B1-D6B5-49D0-B8D0-8493F1530C83Q38177871-5CCFD9A8-0A48-42A6-B8FF-BD06ABD7B5ACQ38666303-60469D7F-D089-41E7-9CC6-BC899B4583BBQ38723319-E8644D7D-6931-4820-9153-16D80A065052Q38808485-2793B471-4594-438E-B985-51BA718C3A85Q38873695-D48DBFE5-E6DC-459B-86D6-2A3FB7D21CE7Q38879765-D5EBA62E-9B91-4775-9ADF-0C9013CB58EBQ38910574-5AEDD050-8386-4EFD-903C-8DBF729F26C3Q39021942-15BD4D7A-8AD5-4AE3-9F26-EB3157DEF71BQ39022643-21F4A888-7ADC-4665-BD17-F31E71388003Q39098884-EBED7E24-27C6-4D65-B731-7AA580C06157Q39795220-E0E56A41-DBF7-46A1-8404-B0A6E040023BQ40133625-294FAE33-0508-49D2-A19F-A90688BE529AQ41014662-33378558-007F-4ABC-A765-B98A4B9CB0F4Q41197913-4666A6DB-7920-478F-A832-5BBDAA838D07Q41369774-F2E7C773-1649-4FDF-B8DB-5177FD2D1E8DQ41488417-9368B17E-A218-4701-A33E-3ED9B4D73DDDQ45977173-2E9F857F-3AF1-4B76-9DF3-04E35FCFCD29Q46023940-1DD07B71-E858-4923-9993-51D8A3777E5D
P2860
Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.
@en
Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.
@nl
type
label
Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.
@en
Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.
@nl
prefLabel
Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.
@en
Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.
@nl
P2093
P2860
P356
P1433
P1476
Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.
@en
P2093
Elizabeth Fisher
Jack H Simon
Pamela Foulds
Richard A Rudick
Robert A Bermel
Robert Hyde
Xiaojun You
P2860
P304
P356
10.1002/ANA.23758
P577
2013-01-01T00:00:00Z